United-Guardian, Inc. (NASDAQ: UG) announced financial results for the third quarter and first nine months of 2026 via a Form 8-K filed on November 9, 2026. The company reported a significant increase in net sales and net income for the three and nine-month periods ended September 30, 2026.
For the third quarter of 2026, net sales rose to $3,494,780, an increase of 54% compared to $2,264,261 in the same period of 2025. Net income for the quarter increased by 247% to $930,912, or $0.20 per share, compared to $268,441, or $0.06 per share, in 2025.
Over the first nine months of 2026, net sales increased 25% to $9,475,269 from $7,583,613 in the prior year. Net income for the nine-month period grew 70% to $2,478,393, or $0.54 per share, compared to $1,456,162, or $0.32 per share, in 2025.
Company President Donna Vigilante attributed the growth to increases in pharmaceuticals, personal care, and medical lubricants. Pharmaceutical sales grew 29% year-over-year, driven primarily by Renacidin, a pharmaceutical product. Cosmetic ingredient sales surged 187% over the same period, led by increased purchases from Ashland Specialty Ingredients (ASI). Medical lubricants also grew 20% compared to the same period in 2025, reflecting increased purchases from a customer in India.
Vigilante noted that the company is in the process of determining marketing efforts to increase awareness of Renacidin among healthcare professionals. Additionally, the company has a new product in late-stage development for the personal care sector that is planned for launch early next year.
